Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Lexaria Bioscience Corp (NQ: LEXX ) 3.910 +0.680 (+21.05%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 30, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Lexaria Bioscience Corp < Previous 1 2 ... 17 18 19 20 21 22 23 24 Next > CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Study Results Expected to Demonstrate DehydraTECH-CBD’s Effectiveness Against Hypertension December 14, 2021 Via CannabisNewsWire Exposures Product Safety Lexaria's Clinical Hypertension Study HYPER-H21-3 Nears Completion December 14, 2021 KELOWNA, BC / ACCESSWIRE / December 14, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that its human... From Lexaria Bioscience Corp. Via AccessWire Lexaria’s (NASDAQ: LEXX) Upcoming R&D Programs Targeting Global Markets Exceeding $160B December 13, 2021 Via Investor Brand Network Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Upcoming R&D Programs Targeting Global Markets Totaling Over $160 Billion December 10, 2021 Via Investor Brand Network Lexaria Bioscience Corp. (NASDAQ: LEXX) Improving Bioavailability of Pharmaceuticals and Therapeutics December 08, 2021 Via CannabisNewsWire Lexaria Bioscience Corp. (NASDAQ: LEXX) Improving Bioavailability of Pharmaceuticals and Therapeutics December 08, 2021 Via Investor Brand Network CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Follow-Up Study Results Confirming DehydraTECH(TM)-CBD Arterial Stiffness Reduction December 08, 2021 Via CannabisNewsWire CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Follow-Up Study Results Confirming DehydraTECH(TM)-CBD Arterial Stiffness Reduction December 08, 2021 Via Investor Brand Network Lexaria's DehydraTECHTM-CBD Reduces Arterial Stiffness, Results Confirmed in Human Clinical Study HYPER-H21-2 December 08, 2021 Results suggest broader applications for DehydraTECH-CBD beyond hypertension KELOWNA, BC / ACCESSWIRE / December 8, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or... From Lexaria Bioscience Corp. Via AccessWire Topics Intellectual Property Exposures Intellectual Property Lexaria Bioscience Corp. (NASDAQ: LEXX) Featured in Virtual Coverage of Benzinga’s Small Cap Conference December 07, 2021 Via Investor Brand Network CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) to Participate in Upcoming Benzinga Global Small Cap Conference December 07, 2021 Via CannabisNewsWire CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) to Participate in Upcoming Benzinga Global Small Cap Conference December 07, 2021 Via Investor Brand Network CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Embarking on Potentially Pivotal Study to Evaluate DehydraTECH-CBD December 02, 2021 Via CannabisNewsWire CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Embarking on Potentially Pivotal Study to Evaluate DehydraTECH-CBD December 02, 2021 Via Investor Brand Network CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Demonstrates 10-20X Faster Nicotine Delivery in Recent Study November 24, 2021 Via CannabisNewsWire CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Demonstrates 10-20X Faster Nicotine Delivery in Recent Study November 24, 2021 Via Investor Brand Network Lexaria Bioscience Corp. (NASDAQ: LEXX) DehydraTECH(TM) Drug Delivery Technology Finding Multiple Medical Applications November 24, 2021 Via Investor Brand Network Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces 2022 DehydraTECH(TM) R&D Programs, Including Investigations into Alzheimer’s Disease and Diabetes November 18, 2021 Via Investor Brand Network Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces 2022 DehydraTECH(TM) R&D Programs, Including Investigations into Alzheimer’s Disease and Diabetes November 18, 2021 Via CannabisNewsWire Lexaria Bioscience Corp. (NASDAQ: LEXX) Embarks on its Most Ambitious Hypertension Clinical Study Yet: HYPER-H21-4 November 12, 2021 Via Investor Brand Network CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands 2022 R&D Programs to Evaluate Potential Treatment Options for Alzheimer’s and Diabetes November 10, 2021 Via CannabisNewsWire CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands 2022 R&D Programs to Evaluate Potential Treatment Options for Alzheimer’s and Diabetes November 10, 2021 Via Investor Brand Network Lexaria 2022 R&D Programs to Include Investigations into Alzheimer's Disease and Diabetes November 10, 2021 KELOWNA, BC / ACCESSWIRE / November 10, 2021 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces its plans for... From Lexaria Bioscience Corp. Via AccessWire Topics Death Intellectual Property Exposures Death Intellectual Property Lexaria Bioscience Corp. (NASDAQ: LEXX) Commences New Animal Study Evaluating Patented DehydraTECH(TM) Technology’s Efficacy in Reducing/Inhibiting Seizure Activity; Strengthens IP Portfolio November 03, 2021 Via Investor Brand Network CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) to Expand Hypertension Clinical Program Through Most Ambitious Study to Date November 03, 2021 Via CannabisNewsWire CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) to Expand Hypertension Clinical Program Through Most Ambitious Study to Date November 03, 2021 Via Investor Brand Network Lexaria Announces Ambitious New Hypertension Study HYPER-H21-4 November 03, 2021 - DehydraTECH-CBD also being evaluated in three other human clinical studies - Positive studies would support Lexaria's regulatory approval plans KELOWNA, BC / ACCESSWIRE / November 3, 2021 / Lexaria... From Lexaria Bioscience Corp. Via AccessWire Topics Intellectual Property Exposures Intellectual Property CBDNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Begins R&D Program Comparing DehydraTECH-CBD with Generic CBD, Epidiolex November 01, 2021 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Lexaria Announces R&D Program to Compare First and Only FDA-Approved Prescription Cannabidiol November 01, 2021 - New study EPIL-A21-1 will compare effectiveness of FDA-approved Epidiolex to DehydraTECHTM-CBD for reducing seizure activity KELOWNA, BC / ACCESSWIRE / November 1, 2021 / Lexaria Bioscience Corp.... From Lexaria Bioscience Corp. Via AccessWire Topics Intellectual Property Exposures Intellectual Property CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Earns Coverage for DehydraTECH(TM)’s Potential Market Reach, Multiple Uses October 29, 2021 Via Investor Brand Network < Previous 1 2 ... 17 18 19 20 21 22 23 24 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.